DTIL - Precision BioSciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Precision BioSciences, Inc.

Dibrell Building
Suite A-100 302 East Pettigrew Street
Durham, NC 27701
United States
919-314-5512
http://www.precisionbiosciences.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees184

Key Executives

NameTitlePayExercisedYear Born
Mr. Matthew R. KaneCo-Founder, CEO, Pres & Director518.52kN/A1977
Mr. Abid AnsariChief Financial Officer347.55kN/A1978
Dr. David S. Thomson Ph.D.Chief Operating Officer490.25kN/A1961
Dr. Jefferson J. Smith Ph.D.Co-Founder & CTON/AN/AN/A
Dr. Derek Jantz Ph.D.Co-founder, Chief Scientific Officer & DirectorN/AN/A1976
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.

Corporate Governance

Precision BioSciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.